Orion Research Foundation grants EUR 1 million for research
Orion and Finland are both celebrating their centenaries in 2017. The Orion Research Foundation is distributing a total of EUR 1 million in research grants today. To celebrate Finland's centenary, the total sum will include an additional gift to Finland in the form of two Orion 100 grants, each worth EUR 100,000. These grants will be awarded to Johanna Ivaska and Mikko Niemi, internationally acclaimed Finnish researchers.
The research grants will be received by Johanna Ivaska, Academy Professor of Biochemistry, University of Turku, and Mikko Niemi, Professor of Pharmacogenetics, University of Helsinki. They will receive an award of EUR 100,000 each for the advancement of significant research. The grants are a gift to Finland by Orion, business partner in the Finland 100 project.
Established in 1957, Orion Research Foundation will also distribute a total of EUR 800,000 to about a hundred researchers, based on their applications, for research in medicine, veterinary medicine, pharmacy and related sciences, such as chemistry and physics, in 2017. Most of the grants are intended for doctoral dissertation work and postdoctoral research by young researchers.
The recipients of the grants are selected by the Board of Directors that consists of two representatives from Orion as well as from the scientific organisations in the field and the five medical educational units in Finland. The Chairman of the Board is Risto Renkonen, Dean of the Faculty of Medicine at the University of Helsinki.
"Ivaska and Niemi are world-leading researchers in the field of medicine and pharmacology. Orion Research Foundation wants to build well-being through new innovations. Ivaska and Niemi are internationally recognised researchers with their dynamic research teams, producing new generations of researchers in Finland," says Risto Renkonen, Chairman of the Board.
Two leading scientists in international research
One of the recipients of the grant, Johanna Ivaska is an internationally distinguished researcher specialising in the role of intracellular changes in metastatic development in cancer. The innovative approach of her research will provide significant new data on the migration and traffic of cancer cells in tissue. Ivaska's research is anticipated to lead to scientific breakthroughs in biomedicine, a very topical field of research today. Twice during her career, Ivaska has received research funding awarded by European Research Council (ERC), which is among the most notable grants in the world and is subject to tough competition.
The other recipient of Orion's centenary grants, Mikko Niemi, is an internationally renowned researcher of pharmacogenetics. Niemi specialises in the effects of genetic differences on drug efficacy and safety. At the core of his research are the hundreds of different transporter proteins in cell membranes carrying chemicals to and from cells. The significance of proteins as drug transporters has only emerged in recent years. The aim of his research is to find safer and more tailored pharmaceutical treatment. Like Ivaska, Niemi has also received the ERC funding twice.
Building the Future Together - Academic Medicine and Pharma is a scientific symposium organised by Orion Research Foundation on 10 February 2017 as part of Orion 100 anniversary year and Finland 100 business partnership. Orion's theme for the centenary year is "Building well-being. Together."
The names of the researchers (94 persons) receiving grants on the basis of their applications will be published on 10 February 2017 at 1.30 p.m.on orion.fi/en website.
Chairman of the Board, Orion research Foundation
Dean, Faculty of Medicine, University of Helsinki
Tel: +358 (0)40 553 5219
SVP, Pharmaceutical R&D,
Chief Medical Officer, Orion Corporation
Phone +358 (0)50 966 3647
VP, Communications, Orion Corporation
Phone +358 (0)50 966 4646
Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2016 amounted to EUR 1,074 million and the company had about 3,500 employees. Orion's A and B shares are listed on Nasdaq Helsinki. Founded in 1917, Orion is celebrating its centenary in 2017.
Orion Research Foundation supports research in the fields of medicine, veterinary medicine and pharmacy and related sciences, such as chemistry and physics. The foundation awards grants to young researchers in these fields, mostly for dissertation work. The funds used for grants mainly originate from the proceeds of the Foundation's investment activities. The Foundation receives part of its funding annually from Orion Corporation. This sum is included in Orion Corporation's proposal on the distribution of profits and is confirmed separately in the Annual General Meeting every year. Orion Research Foundation independently decides on the distribution of grants and is a unit independent from the Orion Group.